Muscle Spasticity Market, by Drug Type (Baclofen, Botulinum Toxin, Diazepam, Tizanidine, Dantrolene Sodium, and Others), by Route of Administration (Oral, Intramuscular, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Onl
Description
Muscle Spasticity Market, by Drug Type (Baclofen, Botulinum Toxin, Diazepam, Tizanidine, Dantrolene Sodium, and Others), by Route of Administration (Oral, Intramuscular, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
When muscles become stiff or contract, the condition is called as muscle spasticity. Muscle spasticity is seen in a variety of conditions such as spinal cord injury, brain injury, diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). It occurs when the nerve impulses involved in controlling muscle movement are either damaged or interrupted. Muscle spasticity can cause a difficulty in talking, moving, or stretching.
Symptoms of muscle spasticity include increased muscle tone, involuntary movements, abnormal posture, pain or discomfort, bone and joint deformities, decreased ability to function, and others. Spasticity should be treated when it causes pain, interferes with daily activities or sleep, or leads to decreased ability to function. Treatment given is based on the patient’s needs, preferences, and goals. The treatment includes physical therapy, occupational therapy, casting or bracing, and oral medications. Surgery may also be needed in certain cases. Oral medications are only used when the symptoms interfere with daily activities or sleep. Common medications include baclofen, dantrolene sodium, botulinum toxin, diazepam, and others.
Market Dynamics
The increasing launches of new drugs and regulatory approvals for muscle spasticity are expected to drive the market growth during the forecast period. For instance, in July 2021, Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, jointly announced that Teijin Pharma was granted additional approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin (incobotulinumtoxinA), a neurotoxin treatment for intramuscular injection in 50, 100 or 200 units for the treatment of lower limb spasticity.
Key features of the study:
This report provides an in-depth analysis of the global muscle spasticity market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global muscle spasticity market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Ipsen Pharma, Allergan, Acorda Therapeutics, Inc., Merz Pharma, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Ltd., Johnson & Johnson Private Limited, Zydus Cadila, F. Hoffmann-La Roche Ltd., and Elite Pharmaceuticals Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global muscle spasticity market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global muscle spasticity market
Detailed Segmentation:
Global Muscle Spasticity Market, By Drug Type:
Baclofen
Botulinum Toxin
Diazepam
Dantrolene Sodium
Others
Global Muscle Spasticity Market, By Route of Administration:
Oral
Intramuscular
Others
Global Muscle Spasticity Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Muscle Spasticity Market, By Region:
North America
Drug Type
Baclofen
Botulinum Toxin
Diazepam
Dantrolene Sodium
Others
Route of Administration
Oral
Intramuscular
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
Drug Type
Baclofen
Botulinum Toxin
Diazepam
Dantrolene Sodium
Others
Route of Administration
Oral
Intramuscular
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Drug Type
Baclofen
Botulinum Toxin
Diazepam
Dantrolene Sodium
Others
Route of Administration
Oral
Intramuscular
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Drug Type
Baclofen
Botulinum Toxin
Diazepam
Dantrolene Sodium
Others
Route of Administration
Oral
Intramuscular
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Drug Type
Baclofen
Botulinum Toxin
Diazepam
Dantrolene Sodium
Others
Route of Administration
Oral
Intramuscular
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
Drug Type
Baclofen
Botulinum Toxin
Diazepam
Dantrolene Sodium
Others
Route of Administration
Oral
Intramuscular
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region/Country
South Africa
Central Africa
North Africa
Company Profiles
Ipsen Pharma
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Allergan
Acorda Therapeutics, Inc.
Merz Pharma
Teva Pharmaceutical Industries Ltd.
Novartis AG
Sun Pharmaceutical Industries Ltd.
Beximco Pharmaceuticals Ltd.
Johnson & Johnson Private Limited
Zydus Cadila
Hoffmann-La Roche Ltd.
Elite Pharmaceuticals Inc.
“*” marked represents similar segmentation in other categories in the respective section.
When muscles become stiff or contract, the condition is called as muscle spasticity. Muscle spasticity is seen in a variety of conditions such as spinal cord injury, brain injury, diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). It occurs when the nerve impulses involved in controlling muscle movement are either damaged or interrupted. Muscle spasticity can cause a difficulty in talking, moving, or stretching.
Symptoms of muscle spasticity include increased muscle tone, involuntary movements, abnormal posture, pain or discomfort, bone and joint deformities, decreased ability to function, and others. Spasticity should be treated when it causes pain, interferes with daily activities or sleep, or leads to decreased ability to function. Treatment given is based on the patient’s needs, preferences, and goals. The treatment includes physical therapy, occupational therapy, casting or bracing, and oral medications. Surgery may also be needed in certain cases. Oral medications are only used when the symptoms interfere with daily activities or sleep. Common medications include baclofen, dantrolene sodium, botulinum toxin, diazepam, and others.
Market Dynamics
The increasing launches of new drugs and regulatory approvals for muscle spasticity are expected to drive the market growth during the forecast period. For instance, in July 2021, Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, jointly announced that Teijin Pharma was granted additional approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin (incobotulinumtoxinA), a neurotoxin treatment for intramuscular injection in 50, 100 or 200 units for the treatment of lower limb spasticity.
Key features of the study:
This report provides an in-depth analysis of the global muscle spasticity market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global muscle spasticity market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Ipsen Pharma, Allergan, Acorda Therapeutics, Inc., Merz Pharma, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Ltd., Johnson & Johnson Private Limited, Zydus Cadila, F. Hoffmann-La Roche Ltd., and Elite Pharmaceuticals Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global muscle spasticity market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global muscle spasticity market
Detailed Segmentation:
Global Muscle Spasticity Market, By Drug Type:
Baclofen
Botulinum Toxin
Diazepam
Dantrolene Sodium
Others
Global Muscle Spasticity Market, By Route of Administration:
Oral
Intramuscular
Others
Global Muscle Spasticity Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Muscle Spasticity Market, By Region:
North America
Drug Type
Baclofen
Botulinum Toxin
Diazepam
Dantrolene Sodium
Others
Route of Administration
Oral
Intramuscular
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
Drug Type
Baclofen
Botulinum Toxin
Diazepam
Dantrolene Sodium
Others
Route of Administration
Oral
Intramuscular
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Drug Type
Baclofen
Botulinum Toxin
Diazepam
Dantrolene Sodium
Others
Route of Administration
Oral
Intramuscular
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Drug Type
Baclofen
Botulinum Toxin
Diazepam
Dantrolene Sodium
Others
Route of Administration
Oral
Intramuscular
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Drug Type
Baclofen
Botulinum Toxin
Diazepam
Dantrolene Sodium
Others
Route of Administration
Oral
Intramuscular
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
Drug Type
Baclofen
Botulinum Toxin
Diazepam
Dantrolene Sodium
Others
Route of Administration
Oral
Intramuscular
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region/Country
South Africa
Central Africa
North Africa
Company Profiles
Ipsen Pharma
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Allergan
Acorda Therapeutics, Inc.
Merz Pharma
Teva Pharmaceutical Industries Ltd.
Novartis AG
Sun Pharmaceutical Industries Ltd.
Beximco Pharmaceuticals Ltd.
Johnson & Johnson Private Limited
Zydus Cadila
Hoffmann-La Roche Ltd.
Elite Pharmaceuticals Inc.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
192 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Key Highlights
- Pipeline Analysis
- Regulatory Scenario
- Product Launches / Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger, Collaboration and Acquisitions Scenario
- 4. Global Muscle Spasticity Market – Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply side and Demand Side Analysis
- Economic Impart
- 5. Global Muscle Spasticity Market, By Drug Type, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Baclofen
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Botulinum Toxin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Diazepam
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Tizanidine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Dantrolene Sodium
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- 6. Global Muscle Spasticity Market, By Route of Administration, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- 7. Global Muscle Spasticity Market, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- 8. Global Muscle Spasticity Market, By Region, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 - 2028, (US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 - 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 - 2028, (US$ Mn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 - 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 - 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Region/Countries, 2017 - 2028, (US$ Mn)
- North Africa
- Central Africa
- South Africa
- 9. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Ipsen Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Allergan
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Acorda Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merz Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Beximco Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson Private Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Zydus Cadila
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- F. Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Elite Pharmaceuticals Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
- 10. Section
- Research Methodology
- About us
- *Browse 29 market data tables and 33 figures on "Muscle Spasticity Market” - Global forecast to 2028
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
